alexa Down Syndrome | Ireland | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Read more

Recommended Journals

Relevant Topics

Down Syndrome

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Down Syndrome

    For centuries, people with Down syndrome have been alluded to in art, literature and science. It wasn’t until the late nineteenth century, however, that John Langdon Down, an English physician, published an accurate description of a person with Down syndrome. It was this scholarly work, published in 1866, that earned Down the recognition as the “father” of the syndrome.Down syndrome is usually caused by an error in cell division called nondisjunction. However, two other types of chromosomal abnormalities, mosaicism and translocation, are also implicated in Down syndrome although to a much lesser extent. Regardless of the type of Down syndrome a person may have, all people with Down syndrome have an extra, critical portion of chromosome 21 present in all or some of their cells. This additional genetic material alters the course of development and causes the characteristics associated with the syndrome. There are more than 50 features of Down syndrome. But not every person with Down syndrome has all the same features or health problems.

  • Down Syndrome

    Some features and problems are common: Body shape and size include Short stature, Low muscle tone, wide neck, Short, stocky arms and legs Face shape and features, Slanted eyes, A nasal bridge that looks pushed in, Small ears,  Irregular teeth

  • Down Syndrome

    The diagnosis is done in two stages i.e during pregnancy and after birth during pregnancy screening tests and diagnostic tests are done . If Down syndrome was not diagnosed before your baby was born, doctors can often get a clear sense of whether your child has Down syndrome by how your baby looks and by doing a physical exam. Treatment for Down syndrome focuses on making sure that your child has regular medical checkups, helping your child develop, watching for early signs of health problems, and finding support. With treatment and support, you can help your child live a happy, healthy life. All people with Down syndrome experience cognitive delays, however, the effect is usually mild to moderate and is not indicative of the many strengths and talents that each individual possesses. Early intervention services, which begin shortly after birth, help children with Down syndrome develop to their full potential. The physical, speech and occupational therapies that early intervention programs provide can enhance a child’s development and provide a way for parents to track their child’s progress.

Expert PPTs

Speaker PPTs

  • Georgia Torres
    Effect of exercise intervention programs on anthropometric, physiological and cardiometabolic parameters of persons with and without metabolic syndrome
    PPT Version | PDF Version
  • Mandob Enyegue Damaris
    Prevalence of metabolic syndrome among University of Yaounde I campus police workers
    PPT Version | PDF Version
  • Danielle Venturini
    Increased oxidative stress according to number of risk factors in metabolic syndrome patients
    PPT Version | PDF Version
  • Thomas Boldicke
    Recent highlights of in vivo knockdown by intrabodies
    PPT Version | PDF Version
  • Laidoudi Aicha
    Acute renal failure and uveitis, which diagnosis is most likely in internal medicine? Tinu syndrome, through two observations
    PPT Version | PDF Version
  • Emanuele Corongiu
    Role of percutaneous tibial nerve stimulation in the treatment of neurogenic overactive bladder syndrome.
    PPT Version | PDF Version
  • Randhawa Ramanpreet
    Receiver Operating Characteristic curve analysis of Anthropometric Physiological and Biochemical indices and a comparison between four International definitions JSS, mATP-III, IDF and ATP-III for screening Metabolic Syndrome among Pre- and Postmenopausal Rural females of Amritsar (Punjab)
    PPT Version | PDF Version
  • Nisreen K Aref
    To compare serum leptin levels in obese women with polycystic ovary syndrome (PCOS) and normal ovulatory obese subjects in Saudi Arabia, and to evaluate the interrelationship between leptin concentration, sex hormones, and insulin resistance.
    PPT Version | PDF Version
  • Monica C Chuong
    Bioprocess Development Upstream and Downstream Technologies
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Elena Rampanelli
    Renal dysfunction and metabolic syndrome: the chicken or the egg?
    PPT Version | PDF Version
  • David Stejskal
    New marker of metabolic syndrome
    PPT Version | PDF Version
  • Vladimir Obolensky
    No-air-plasma currents and ozone therapy in treatment of patients with diabetic foot syndrome
    PPT Version | PDF Version
  • Wentao Zhou
    Patient centered transitional care for patients transferred from Intensive Care Unit (ICU) to step-down care unit: A mixed method study
    PPT Version | PDF Version
  • Kirill Shlyapnikov
    Fibromyalgia and chronic fatigue syndrome (CFS): translational biomarkers as applicable to monitor and to predict clinical manifestations
    PPT Version | PDF Version
  • Ljudmila Stojanovich
    The risk of thrombosis in patients with antiphospholipid syndrome: Influence of antiphospholipid antibody type and levels
    PPT Version | PDF Version
  • Tamer I Mahmoud
    Early Life Intervention Diminishes Manifestations of Sjögren's Syndrome in NOD.H-2h4 mice
    PPT Version | PDF Version
  • Calsolaro Valeria
    METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF THE ART AND DATA FROM A SECOND LEVEL OUTPATIENT CLINIC IN ITALY
    PPT Version | PDF Version
  • Roger W Beuerman
    Breaking down barriers to promote effective antibiotic action
    PPT Version | PDF Version
  • Mariana Artimos da Matta Tenorio
    Wilkie’s Syndrome: A Case Report
    PPT Version | PDF Version
  • Alex Constantinescu
    Strategies to minimize growth retardation in children with Steroid-sensitive nephrotic syndrome
    PPT Version | PDF Version
  • Irma Esther Del Moral Espinosa
    Effectiveness of combination prednisone tacrolimus compared with prednisone -cyclosporine in treatment steroid-resistant nephrotic syndrome
    PPT Version | PDF Version
  • Pupalan Iyngkaran
    Region Specific Cardiology Perspectives on the Cardiorenal Syndrome – Challenges and Solutions
    PPT Version | PDF Version
  • Sandra Rasmussen
    Live well: A recovery model for addiction and other reward deficiency syndrome
    PPT Version | PDF Version
  • Rafael Correa-Rocha
    HIV infection of Human regulatory T cells (Treg) downregulates Foxp3 expression and produces a loss of the suppressive capacity of these cells
    PPT Version | PDF Version
  • Emmanuel C. Besa
    New opportunities in a personalized approach to the preleukemic phase of myelodysplastic syndrome and acute myelogenous leukemia
    PPT Version | PDF Version
  • Amera Elzubier
    Lemierres syndrome: The forgotten disease? A case report
    PPT Version | PDF Version
  • Malgorzata Lipinska Gediga
    Endothelium as a part of septic Multiple Organ Dysfunction Syndrome (MODS)-is endocan an answer ?
    PPT Version | PDF Version
  • Martha M Sklavos
    PDF Version
  • Tao Wu
    The association between TCM syndromes and SCAP polymorphisms insubjects with non-alcoholic fatty liver disease
    PPT Version | PDF Version
  • Galya Naydenova Atanasova
    Pulse pressure and apolipoprotein B/Apolipoprotein A1 in relation to the metabolic syndrome and its components
    PPT Version | PDF Version
  • Edward Rojas
    PDF Version
 

High Impact List of Articles

Conference Proceedings

adwords